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Single- versus Dual-Coil ICD Leads. Background: Current data on efficacy, safety and impact on
clinical outcome of single- versus dual-coil implantable cardioverter-defibrillator (ICD) leads are limited
and contradictory.
Methods: Defibrillation threshold (DFT) at implantation and first shock efficacy were compared in pa-
tients implanted with single- versus dual-coil ICD leads in MADIT-CRT. The risk for atrial tachyarrhyth-
mias and all-cause mortality were evaluated. Short- (<30 days after the implantation) and long-term
(throughout the entire study duration) complications were assessed.
Results: Patients with dual-coil ICD leads had significantly lower DFTs compared to patients with single-
coil ICD leads (17.6 ± 5.8 J vs 19.4 ± 6.1 J, P < 0.001). First shock efficacy was similar among patients
with dual and single-coil ICD leads (89.6% vs 92.3%, P = 1.00). When comparing patients with dual versus
single-coil ICD leads, there was no difference in the risk of atrial tachyarrhythmias (HR = 1.57, 95%
CI: 0.81–3.02, P = 0.18), or in the risk of all-cause mortality (HR = 1.10, 95% CI: 0.58–2.07, P = 0.77).
Patients implanted with single- or dual-coil ICD lead had similar short and long-term complication rates
(short-term HR = 0.96, 95% CI: 0.56–1.65, P = 0.88, long-term procedure-related HR = 0.99, 95% CI:
0.62–1.59, P = 1.00, long-term ICD lead related: HR = 1.2, 95% CI: 0.5–2.9, P = 0.68) during the mean
follow-up of 3.3 years.
Conclusions: Patients with single-coil ICD leads have slightly higher DFTs compared to those with dual-
coil leads, but the efficacy, safety, and clinical impact on atrial tachyarrhythmias, and mortality is similar.
Implantation of single-coil ICD leads may be favorable in most patients. (J Cardiovasc Electrophysiol, Vol.
24, pp. 1246-1252, November 2013)
atrial arrhythmias, heart failure, implantable cardioverter defibrillators, MADIT-CRT mortality
Background
With the technological development of cardiac device
therapy, the implantation of dual-coil implantable car-
dioverter defibrillator (ICD) leads has become widespread,
possibly due to the reported lower defibrillation threshold
compared to single-coil ICD leads.1-8 However, small differ-
ences in defibrillation threshold are less likely to be clinically
meaningful with today’s high energy ICD devices.9 Some
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studies also suggested that defibrillation threshold does not
reflect therapy efficacy (shock conversion rate) during the
follow-up.10 Furthermore, dual-coil ICD leads have more
complicated lead structure that might be associated with
higher risk of lead-related complications including lead dis-
lodgement, insulation failure or lead fracture that need lead
extraction.11
We hypothesized that the implantation of dual-coil ICD
leads may result in more atrial tachyarrhythmias when com-
pared to single-coil ICD leads, possibly due to mechanical
irritation of the right atrium caused by the superior vena cava
(SVC) coil. We also hypothesized that dual-coil ICD lead im-
plantations bear higher complication rates when compared to
single-coil ICD leads. To our knowledge, there have been no
large cohort clinical studies investigating the clinical out-
come of atrial tachyarrhythmias and all-cause mortality in
patients with single- and dual-coil ICD leads. Therefore, the
aim of our study was to evaluate the clinical impact, efficacy,
and safety of single- versus dual-coil ICD leads by evaluating
the defibrillation threshold, complication rate, and first shock
efficacy, and to assess the risk of atrial tachyarrhythmias and
all-cause mortality in patients receiving single- versus dual-
coil ICD lead systems, enrolled in MADIT-CRT.
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Methods
MADIT-CRT
The protocol and primary results of the MADIT-CRT
study have previously been published.12,13 Briefly, 1,820
patients with ischemic or nonischemic cardiomyopathy, an
ejection fraction ≤ 30% and a prolonged interventricular
conduction delay with QRS complexes >130 milliseconds
were randomized in a 3:2 fashion to CRT-D or ICD. Patients
were excluded from the study if they had an existing indica-
tion for implantation with CRT-D, NYHA class III or IV or
myocardial infarction within 90 days prior to enrollment, or
those with permanent atrial fibrillation, or paroxysmal atrial
fibrillation at the time of enrollment.
The study was conducted in the period from December 22,
2004 through June 24, 2009, at which time it was stopped
by the recommendation of the data safety monitoring board.
An extended follow-up was conducted until September 10,
2010.
This study comprised all patients who received an ICD
or CRT-D device in MADIT-CRT (n = 1,790). We excluded
7 patients who had a subcutaneous array implanted during
the implantation procedure (n = 1,783). Three patients had a
single-coil RV lead implanted together with a SVC coil; they
were categorized as dual-coil patients.
Device Programming and Interrogation
Commercially available ICD and CRT-D devices from
Boston Scientific were used in this trial and standard transve-
nous mechanisms for implantation were followed. The im-
plantation of a single- or dual-coil ICD lead was left to the dis-
cretion of the implanting physician. ICD and CRT-D devices
were programmed according to the prespecified protocol,12
having a ventricular tachycardia (VT) zone programmed at
180 beats per minute (bpm) and the ventricular fibrillation
(VF) zone at 210 bpm. Sensitivity was set at the physician’s
discretion. The detection duration was recommended to be
2.5 seconds in the VT zone and 1.0 seconds in the VF zone
according to current standards.
The protocol suggested programming the first VT zone
therapy to burst-type antitachycardia pacing (ATP) with 8
pulses at 88% of the measured cycle length with a 10 ms
decrement between bursts, and shock therapy at the defib-
rillation threshold plus at least 10 J, then maximum energy
biphasic shocks.
All ICD and CRT-D devices were interrogated 1 month
after enrollment and every 3 months thereafter until the end of
the trial. All interrogation discs were sent to an independent
core-laboratory for final adjudication.
Defibrillator Threshold Testing
There was no DFT testing protocol described for patients
enrolled in MADIT-CRT and the decision whether or not
to perform DFT testing was left to the discretion of the im-
planting physician. Additionally, it was not specified if the
enrolling centers should use the stepwise approach or an em-
piric value to evaluate the defibrillation threshold. As a result,
a variety of different methods were observed to establish the
baseline defibrillation threshold. However, the majority of
patients (91%) did undergo DFT testing within 1 month of
device implant. Prior results have shown that the method of
VF induction during DFT testing does not affect the DFT test
results.14
Endpoints
The endpoints of the current analysis comprised defibrilla-
tor threshold (DFT) testing data at implantation, short-term
(<30 days) and long-term complication rates, and the oc-
currence of atrial tachyarrhythmias and all-cause mortality
during the follow-up.
Short-term procedure-related complications were ana-
lyzed from the reported adverse events and defined as any
complication occurring within the first 30 days after implan-
tation that required either active resuscitation (cardiac arrest,
VT/VF or respiratory arrest) or invasive procedures due to
complications such as pneumothorax, hemothorax, coronary
dissection, tamponade, atrial perforation, infection needing
surgery, hematoma or hemorrhage.
Long-term right ventricular lead related complications
were captured throughout the entire duration of the study
and comprised lead dislodgement, insulation failure, lead
fracture, high ventricular threshold, coil fracture, over- or
undersensing and postimplant myocardial perforation.
First shock efficacy, defined as a first spontaneous clinical
occurrence of a VT or VF episode where 1 shock successfully
terminated the ventricular arrhythmia, was assessed from in-
dependently adjudicated appropriate therapy episodes from
device interrogation electrograms and defined as 1 appropri-
ate ICD shock in a VT or VF episode.
Atrial tachyarrhythmias were captured from the ICDs dur-
ing follow-up and adjudicated by an independent adjudica-
tion committee from the EGMs and comprised atrial fibrilla-
tion, atrial flutter, regular supraventricular tachycardia, and
atrial tachycardia events. Combined assessment of atrial fib-
rillation and atrial flutter was considered as a separate end
point.
Ventricular arrhythmias were also captured from the ICDs
during follow-up and adjudicated by an independent adjudi-
cation committee using the EGMs of the episodes.
All-cause mortality was defined as death from any cause,
and was captured during the entire follow-up of the study and
adjudicated by an independent mortality committee blinded
to clinical data or treatment assignment.
Statistical Analysis
Patients were categorized into 2 groups based on whether
a single- or dual-coil ICD lead was implanted. Baseline char-
acteristics were compared between patient subgroups using
nonparametric Wilcoxon or Kruskal–Wallis tests for contin-
uous variables and chi-square test for dichotomous variables,
as appropriate. Defibrillation threshold test results were com-
pared between the patient subgroups using the Kruskal–
Wallis test. The first shock efficacy was compared using
chi-square test and Fisher’s exact test.
Cumulative probability of atrial tachyarrhythmia
episodes, atrial fibrillation/flutter episodes, and all-cause
mortality were displayed according to the Kaplan–Meier
method, with comparisons of cumulative event rates by the
log-rank test.
Multivariate Cox proportional hazard’s regression anal-
yses were performed to estimate the risk of dual- versus
single-coil ICD lead on atrial tachyarrhythmias, atrial fib-
rillation/flutter, all-cause mortality and complications. In the
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TABLE 1
Baseline Clinical Characteristics of Patients with Single- versus Dual-Coil
ICD Leads
Clinical Single-Coil RV Dual-Coil RV
Characteristics Leads (n = 162) Leads (n = 1,621) P Value
Median follow-up
time (months)
35.1 40.5 <0.001
Female 50(31) 395(24) 0.068
Age at enrollment 63.7 ± 9.8 64.6 ± 10.7 0.176
CRT-D treatment 97(60) 978(60) 0.910
Ischemic NYHA
class I
17(10) 243(15) 0.122
Ischemic NYHA
class II
55(34) 665(41) 0.080
Nonischemic
NYHA class II
90(56) 713(44) 0.005
QRS 160.6 ± 18.6 157.8 ± 19.8 0.027
LBBB 129(80) 1,130(70) 0.008
RBBB 18(11) 205(13) 0.571
IVCD 15(9) 284(18) 0.007
BMI 28.6 ± 5.2 28.7 ± 5.3 0.954
Diabetes 42(26) 500(31) 0.191
Hypertension 89(55) 1,045(65) 0.014
Prior MI 51(31) 709(45) 0.001
GFR 71.4 ± 20.5 69.0 ± 20.2 0.217
Antiarrhythmic
drug treatment
9(6) 138(9) 0.192
LVEF 29.5 ± 3.5 29.0 ± 3.4 0.034
LVEDV indexed
by BSA
125.2 ± 30.3 123.0 ± 27.6 0.565
LVESV indexed
by BSA
88.8 ± 24.5 87.8 ± 22.3 0.931
LAV indexed by
BSA
45.8 ± 10.9 46.7 ± 9.9 0.132
Values are given as the percentage of patients or mean ± SD. NYHA =
New York Heart Association class; BMI = body mass index; IVCD = intra-
ventricular conduction delay; GFR = glomerular filtration rate; LAV = left
atrial volume; LBBB = left bundle branch block; LVEDV = left ventricular
end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV =
left ventricular end-systolic volume; MI = myocardial infarction; RBBB =
right bundle branch block.
multivariate model we adjusted for relevant variables selected
by best subset regression analysis. The analysis was stratified
by the location of the enrolling center (outside/inside USA).
A 2-tailed P value below or equal to 0.05 was considered
statistically significant. All analyses were conducted using
SAS statistical software 9.3 version (SAS Institute, Cary,
NC, USA).
Results
Baseline Clinical Characteristics
Baseline clinical characteristics of patients with single-
coil ICD lead (n = 162) versus dual-coil ICD lead (n = 1,621)
are depicted in Table 1. Patients implanted with a single-coil
ICD lead had more often nonischemic cardiomyopathy, wide
QRS duration, LBBB, hypertension, prior MI and less often
an IVCD ECG pattern. Baseline left ventricular ejection frac-
tion (LVEF) was slightly higher in the single-coil ICD lead
patient group compared to patients implanted with a dual-coil
ICD lead. The proportion of CRT-D implantation was sim-
ilar in both subgroups (60%). Medical treatment, including
antiarrhythmic drugs, was similar across the subgroups.
We found a substantial difference in the usage of single-
versus dual-coil ICD leads by the location of the enrolling
TABLE 2A
Defibrillation Threshold Testing Results in Patients with Implanted Single-
and Dual-Coil ICD Leads
Defibrillation Threshold
Single-Coil Leads Dual-Coil Leads P Value
Mean ± SD 19.4 ± 6.1 17.6 ± 5.8 <0.001
TABLE 2B
First Shock Efficacy (1 Single Shock Terminates VT or VF) in Patients
with Implanted Single- and Dual-Coil ICD Leads
First Shock Efficacy
Single-Coil Leads Dual-Coil Leads P Value
Events/patients 12/13 146/163
Percentage 92.3% 89.6% 1.000*
*Fisher’s exact test.
centers. More single-coil leads were implanted outside of the
USA (66% vs 34%, P < 0.001). There have been 82 of 110
centers (75%) using dual-coil ICD leads exclusively. Out of
the 87 US centers, 17 centers implanted a total of 55 single-
coil ICD leads (1–12 leads, 2–22% of all ICD leads per site).
Out of the 23 OUS centers, 11 sites implanted 107 single-coil
ICD leads (1–29 leads, 1–27% of all ICD leads per center).
Defibrillator Threshold Testing, First Shock Efficacy
Defibrillator threshold testing was performed in 1,503 pa-
tients (93%) with dual-coil ICD leads and in 149 patients
(92%) with single-coil ICD leads, within 1 month of the
device implantation.
Patients implanted with a dual-coil ICD lead had a sig-
nificantly lower defibrillation threshold than those with a
single-coil ICD lead (dual coil 17.6 ± 5.8 J, vs single coil
19.4 ± 6.1 J (P<0.001) (Table 2A). However, the difference
was only an average of 1.8 J between single- and dual-coil
ICD lead patients.
Evaluating the efficacy of first shock, we found no differ-
ence in patients implanted with single- or dual-coil ICD leads
(single coil 92.3% vs dual coil 89.6%, P = 1.00) (Table 2B).
Short- and Long-Term Complications
Procedure-related complications within 30 days of im-
plantation occurred in 16 of 162 (10%) patients with single-
coil and in 122 of 1,621 (8%) patients with dual-coil ICD
leads. Right ventricular (RV) lead related complications dur-
ing the mean follow-up time of 40 months occurred in 6
patients with single-coil ICD leads (3.7%) and in 51 patients
with dual-coil ICD leads (3.2%). A total of 71 patients had
their RV lead explanted, 66 patients (3.7%) in the dual-coil
ICD lead group and 5 patients (3.1%) in the single-coil ICD
lead group. There was no significant difference in the crude
event rates in both short-and long-term complications be-
tween the subgroups, as shown in Table 3.
In the multivariate Cox proportional regression model, ad-
justing for gender, ischemic heart disease and enrolling center
there was no difference in short- and long-term procedure-
related complication or in long-term RV-lead related com-
plications among patients implanted with single- or dual-
coil ICD leads using single-coil patients as a reference
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TABLE 3
Short- and Long-Term Complications in Single- versus Dual-Coil ICD
Lead Recipients
Complications
Single Coil Dual-Coil
N = 162 N = 1,621
Total Lead and Procedure-Related Complications within 30 Days
RV lead related 2 (1.2) 19 (1.2)
Procedure related 16 (9.9) 122 (7.5)
Individual Procedure-Related Complications within 30 Days
Cardiac arrest or VT/VF 1 (0.6) 6 (0.4)
Respiratory arrest 1 (0.6) 4 (0.3)
Coronary sinus dissection 0 10 (0.6)
Tamponade 1 (0.6) 9 (0.6)
Pneumothorax or hemothorax 3 (1.9) 23 (1.4)
Hematoma or hemorrhage 10 (6.2) 60 (3.7)
Arterial perforation 0 2 (0.1)
Infection needing operation 0 17 (1.1)
Long-Term Follow-Up
Any RV-lead related complications 6 (3.7) 51 (3.2)
RV lead explantations 5 (3.1) 66 (3.7)
Procedure-related complications 21 (13.0) 171 (10.6)
*Complications are listed as numbers and percentages, all P values are
nonsignificant between the subgroups.
group (short-term procedure-related: HR = 0.96, 95% CI:
0.56–1.65, P = 0.88, interaction with treatment P = 0.92;
long-term procedure-related: HR = 0.99, 95% CI: 0.62–1.59,
P = 1.00, interaction with treatment P = 0.79; and long-term
RV lead related: HR = 1.2, 95% CI: 0.5–2.9, P = 0.68, inter-
action with treatment P = 0.61). Nonsignificant interaction
with treatment P values suggests that patients with single- or
dual-coil ICD leads and an implanted CRT-D do not expe-
rience more short- or long-term complications compared to
ICD patients with single- or dual-coil ICD leads.
There have been 71 (4%) RV lead extractions during the
mean study follow-up of 40 months (median: 41 months), but
there was no significant difference in the proportion of lead
extractions among those implanted with single- or dual-coil
ICD leads.
Atrial Tachyarrhythmias
During the follow-up, 150 patients (9.3%) developed atrial
tachyarrhythmias implanted with dual-coil ICD leads, and
10 patients (6.2%) with single-coil ICD leads (P = 0.247).
Patients with single- versus dual-coil ICD leads had simi-
lar cumulative incidence of atrial tachyarrhythmias (3-year
Kaplan–Meier cumulative event rate of 5% in single-coil
leads vs 9% in dual-coil leads, P = 0.302) (Fig. 1) as was
the incidence of atrial fibrillation or flutter (3-year Kaplan–
Meier cumulative event rate of 4% in both groups, P = 0.94)
(data not shown).
Dual-coil ICD leads were not associated with a signifi-
cantly increased risk of atrial tachyarrhythmias (P = 0.180),
or atrial fibrillation and atrial flutter (P = 0.573) after adjust-
ment for clinical covariates such as treatment, age at enroll-
ment, gender, left bundle branch block (LBBB), ischemic
etiology of cardiomyopathy, body mass index greater than
30, coronary artery bypass graft surgery in the past, revas-
cularization procedure in the past, baseline QRS duration,
left ventricular ejection fraction at baseline, left atrial vol-
ume index at baseline. This was similar in patients with an
TABLE 4
Risk of Atrial Tachyarrhythmias, Atrial Fibrillation, and All-Cause
Mortality in Single- versus Dual-Coil ICD Lead Patients
Parameter Hazard Ratio 95% CI P Value
All Atrial Tachyarrhythmias (156 Events/1,718 Patients)
Dual coil:single coil 1.57 0.81–3.02 0.180
Atrial Fibrillation And Atrial Flutter (85 Events/1,718 Patients)
Dual coil:single coil 1.26 0.57–2.79 0.573
All-Cause Mortality (176 Events/1,719 Patients)
Dual coil:single coil 1.10 0.58–2.07 0.771
* Model is adjusted for treatment, age at enrollment, gender, LBBB, ischemic
etiology of cardiomyopathy, body mass index greater than 30, coronary
artery bypass graft surgery in the past, revascularization procedure in the
past, baseline QRS duration, left ventricular ejection fraction at baseline,
and left atrial volume index at baseline. The analysis was stratified by the
location of the enrolling center (outside/inside USA).
implanted ICD or CRT-D (interaction P value with treatment
> 0.1 for both endpoints) (Table 4).
Effect of CRT-D on First Shock Efficacy and Ventricular
Arrhythmias
In patients with ventricular arrhythmias and single-coil
ICD leads implanted, the first shock efficacy was 80% (8 of
10 patients) with an implanted ICD-only, and 100% (5 of
5 patients) with an implanted CRT-D (P = 0.524). In those
implanted with dual-coil ICD leads, 67 of 79 (85%) ICD
patients and 78 of 82 (95%) CRT-D patients had successful
first appropriate shock during the follow-up (P = 0.036).
In patients implanted with single-coil ICD lead, there was
a significant reduction in the risk of ventricular tachyarrhyth-
mias from CRT-D when compared to ICD-only patients
(HR = 0.38, 95% CI: 0.18–0.83, P = 0.015). The reduc-
tion in ventricular arrhythmias was also evident in patients
implanted with dual-coil ICD leads and a CRT-D when com-
pared to ICD-only patients (HR = 0.80, 95% CI: 0.65–0.98,
P = 0.028). When comparing patients implanted with a
single-coil ICD lead to patients implanted with a dual-coil
lead, we found a trend toward decreased risk of ventricular
arrhythmias in patients implanted with a single-coil ICD lead
(P = 0.12).
All-Cause Mortality
During the study duration, 175 patients (10.8%) died im-
planted with dual-coil ICD leads, and 12 patients (7.4%)
died implanted with single-coil ICD leads. The cumulative
event rate was not significantly different among these pa-
tient subgroups (P = 0.486) (Fig. 2). Consistent with this,
implantation of a dual-coil ICD lead was not associated with
an increased risk of mortality compared to a single-coil ICD
lead after adjustment for relevant clinical covariates (P =
0.771) (Table 4). This was consistent in ICD and CRT-D
patients (interaction P value with treatment > 0.1).
Sensitivity Analyses
In patients with single-coil ICD leads there was a signif-
icantly shorter follow-up time, and this difference is coming
from the fact that patients were more often implanted with
single-coil ICD leads toward the end of the trial. The percent-
ages of implanted single-coil ICD leads were 7.4% versus
6.2% versus 10.5% versus 17.8%, respectively, for the years
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Figure 1. Atrial tachyarrhythmias in patients with single- versus dual-coil ICD leads.
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Figure 2. Cumulative probability of all-cause mortality in patients with single-, dual-coil ICD leads.
of 2005, 2006, 2007, and 2008. For sensitivity analyses we
stratified the previous multivariate models for the year of en-
rollment and found consistent results: patients with dual-coil
ICD leads had a trend toward a higher risk of atrial tach-
yarrhythmias (HR = 1.59, 95% CI: 0.82–3.08, P = 0.166),
but no difference was observed in atrial fibrillation or atrial
flutter (HR = 1.22, 95% CI: 0.55–2.74, P = 0.626) and in all-
cause mortality (HR = 1.23, 95% CI: 0.65–2.34, P = 0.524).
Discussion
In this study, we demonstrated that ICD and CRT-D pa-
tients implanted with single- versus dual-coil ICD leads have
similar complication rates during implantation and through
the entire study follow-up. Furthermore, we did not find dif-
ferences in atrial arrhythmia burden or all-cause mortality.
However, we did see a trend toward a decreased risk of ven-
tricular arrhythmias in patients implanted with a single-coil
ICD lead compared to patients implanted with a dual-coil
ICD lead. Patients implanted with dual-coil ICD leads had
significantly lower energy requirement during DFT testing,
but this difference was not associated with a better first shock
efficacy during the follow-up.
To our knowledge, this is the first large cohort patient data
comprehensively evaluating defibrillation threshold testing
results, arrhythmia termination success, short- and long-term
complications, mortality, and the incidence of atrial tach-
yarrhythmias in ICD and CRT-D patients implanted with
single- versus dual-coil ICD leads.
Previous small trials did not show differences in DFT
among patients with single- or dual-coil ICD leads. Schulte
et al.6 randomized 83 patients to receive single- or dual-coil
leads and found no difference in ICD energy requirements
or the probability of successful defibrillation. Similar results
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were found by another group in patients with secondary or
primary ICD indications (DFT single- vs dual coil, 10.2 ±
5.2 J vs 10.3 ± 4.1 J, P = NS).7
However, others reported significantly lower defibrillator
thresholds in dual-coil ICD leads compared to single-coil
ICD leads (8.7 ± 4.0 J vs 10.1 ± 5.0 J, P < 0.02).4 These
studies were conducted in small patient cohorts. In our analy-
sis, we confirmed similar results in a large patient cohort. We
found a statistically significant lower defibrillation threshold
in dual-coil ICD leads versus single-coil ICD leads (mean
value, single coil 19.4 J vs dual coil 17.6 J); however, the
clinical value of a 1.8 J reduction in DFTs may be of limited
significance especially with today’s high energy ICDs that
are capable of delivering up to 40 J. This is further proven by
our study results suggesting that the difference in the defib-
rillation threshold was not associated with a difference in the
ICD shock efficacy among patients implanted with single-
versus dual-coil ICD leads.
Furthermore, the actual need and benefit of defibrilla-
tor testing at implantation has recently been questioned.15-17
Michowitz et al.16 suggested that defibrillator testing in 256
CRT-D patients was associated with increased morbidity and
no survival or device benefit during the follow-up. Another
recent trial evaluated the effects of DFT testing in 2,120 con-
secutive patients and showed no significant differences in
procedural complications or sudden cardiac death or resus-
citation during the follow-up.18
Our study is unique in that we have evaluated the inci-
dence of atrial tachyarrhythmias in single- versus dual-coil
ICD recipients. We hypothesized that dual-coil ICD leads
might be associated with more prevalent atrial arrhythmias
because of the mechanical irritation of the left atrium caused
by the SVC coil. Although our results did not support this
hypothesis, there does appear to be a trend toward higher
rates of both atrial and ventricular arrhythmias with dual-
coil ICDs (adjusted P value = 0.18 and 0.12, respectively).
However, the small sample size in the single-coil arm may
have been underpowered to detect a statistically significant
difference. Larger studies are warranted to further evaluate
this association.
When evaluating the first shock efficacy in dual-coil ICD-
only versus CRT-D patients, we found that in CRT-D pa-
tients the first shock in more frequently successful than in
ICD patients. The reason for this association is unknown.
The P value for the difference reached significance, however,
because of the small sample size these data need to be inter-
preted with caution. Larger scale data are needed to further
evaluate the possible advantage of dual-coil ICD leads in
CRT-D patients compared to ICD patients.
Previous studies have not reported on complications in
single- versus dual-coil ICD lead systems. It has also been
questioned whether transvenous lead extraction of dual-coil
leads could be associated with increased risk of mortality
compared to single-coil lead systems due to a higher risk of
complications associated with the extraction procedure.19 In
our study, 71 RV lead extractions were performed during a
mean follow-up of 40 months, but there was no significant
difference in the proportion of lead extractions among those
implanted with single- or dual-coil ICD leads. Furthermore,
we found no evidence for differences in all-cause mortality
between single- and dual-coil ICD lead patients.
We were not able to show a significant difference between
single- and dual-coil ICD leads with regard of the occurrence
of short- and long-term procedure-related complications and
long-term RV ICD lead-related complications.
In this analysis, we had a low number of single-coil ICD
leads. Furthermore, we report a very low complication rate
over a relatively short follow-up time. These factors might
translate into limited statistical power in our analysis to detect
significant differences in complication rate.
With the sample size available in our study, the power to
detect a significant difference in outcomes such as compli-
cation rate or atrial arrhythmias, 7.5% versus 15% is 80%,
which would certainly represent a clinically meaningful dif-
ference for complication rates. The complication rates were
generally much closer than this and so we feel confident
that the lack of statistical significance reflects the true lack
of difference in the complication rates between the 2 device
types. For instance, the RV-lead related complication rates
were 3.7% and 3.2% for single and dual coils, respectively.
Ideally, a larger sample of patients with single-coil devices
would give us more robust findings due to added statistical
power. However, our data are to date the largest study sample
from a randomized clinical trial suggesting that single-coil
ICD leads are not inferior to dual-coil ICD leads. Further
larger, randomized studies may be warranted to explore the
efficacy, safety and the potential atrial proarrhythmic effect
of dual-coil ICD leads.
Another possible limitation of our study is its nonrandom-
ized fashion, which might contribute to potential bias. There
was a difference of 5 months in the median follow-up time
among patients implanted with single- versus dual-coil ICD
leads. Furthermore, in MADIT-CRT, we do not have the pro-
grammed first shock energy available; therefore, the analysis
on the first shock efficacy might be confounded. However,
the defibrillation threshold was very low in both groups, and
using the recommended 10 J safety margin, most patients
might have had similar shock energies programmed.
Conclusion
In this analysis we suggest that patients implanted with
single- versus dual-coil ICD lead have similar short- and
long-term complication rates and there does not appear to
be a difference in atrial arrhythmia burden and in all-cause
mortality. Although patients with a dual-coil ICD system
have a statistically significant lower energy requirement dur-
ing DFT testing, this difference is not associated with better
ICD treatment efficacy. Therefore, it may be reasonable to
consider implantation of single-coil ICD systems in most
patients, except when a higher defibrillation threshold is an-
ticipated before implantation.
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